C WorldWide Group Holding A S Has $47.65 Million Position in DexCom, Inc. (NASDAQ:DXCM)

C WorldWide Group Holding A S boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 384,000 shares of the medical device company’s stock after purchasing an additional 12,000 shares during the period. DexCom comprises approximately 0.6% of C WorldWide Group Holding A S’s holdings, making the stock its 20th largest position. C WorldWide Group Holding A S owned approximately 0.10% of DexCom worth $47,651,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Stableford Capital II LLC raised its position in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after acquiring an additional 88 shares in the last quarter. Valley National Advisers Inc. lifted its stake in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. FORVIS Wealth Advisors LLC boosted its holdings in DexCom by 0.7% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after purchasing an additional 110 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after purchasing an additional 115 shares in the last quarter. Finally, HM Payson & Co. increased its position in DexCom by 8.5% during the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock worth $138,000 after buying an additional 116 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 14,639 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the transaction, the chief operating officer now directly owns 273,913 shares of the company’s stock, valued at approximately $36,816,646.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the sale, the chief operating officer now directly owns 273,913 shares in the company, valued at approximately $36,816,646.33. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock valued at $25,530,859 in the last 90 days. 0.41% of the stock is currently owned by company insiders.

DexCom Stock Performance

DXCM traded down $13.67 on Friday, hitting $124.34. 8,578,184 shares of the stock traded hands, compared to its average volume of 2,409,208. The business has a fifty day moving average price of $131.13 and a two-hundred day moving average price of $118.30. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $49.24 billion, a PE ratio of 80.22, a P/E/G ratio of 2.37 and a beta of 1.20. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.38% and a net margin of 16.82%. On average, research analysts predict that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on DXCM shares. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Raymond James boosted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday. Canaccord Genuity Group upped their price objective on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday. Finally, UBS Group lifted their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.